Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 18/12/2024
• Auteurs : Pierre-Antoine LaurentFabrice AndréAlexandre BobardDesiree DeandreisSandra DemariaS. DepilStefan B EichmüllerCristian Fernandez-PalomoFloris FoijerLorenzo GalluzziJérôme GalonMatthias GuckenbergerKevin J HarringtonFernanda G HerreraPeter E HuberAntoine ItalianoSana D KaramGuido KroemerPhilippe LambinCarola LeuschnerAlberto MantovaniEtienne MeylanMichele MondiniMikael J PittetJean-Pierre PougetJordi RemonClaus S SørensenChristos SotiriouClaire Vanpouille-BoxRalph R WeichselbaumJames W WelshLaurence ZitvogelSilvia C FormentiEric Deutsch
• Organismes : Radiothérapie Moléculaire et Innovation Thérapeutique Institut Gustave Roussy Département de médecine oncologique [Gustave Roussy] Institut Gustave Roussy Médecine nucléaire [Gustave Roussy] Weill Medical College of Cornell University [New York] Sandra and Edward Meyer Cancer Center [New-York] Hospices Civils de Lyon Centre de Recherche en Cancérologie de Lyon ErVimmune, Lyon Universität Bern = University of Bern = Université de Berne University of Groningen [Groningen] Weill Medical College of Cornell University [New York] Sandra and Edward Meyer Cancer Center [New-York] Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA Centre de Recherche des Cordeliers University hospital of Zurich [Zurich] Universität Zürich [Zürich] = University of Zurich The Institute of Cancer Research Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Max Planck Institute for Extraterrestrial Physics Institut Gustave Roussy University of Colorado Anschutz Medical Campus [Aurora] Centre de Recherche des Cordeliers Institut Gustave Roussy Cancer Research and Personalized Medicine - CARPEM [Paris] Maastricht University Medical Centre Organisation Mondiale de la Santé - World Health Organization Regional Office for Europe [Copenhagen] Ecole Polytechnique Fédérale de Lausanne Radiothérapie Moléculaire et Innovation Thérapeutique Harvard Medical School [Boston] Center for Systems Biology [Boston] Massachusetts General Hospital [Boston] Institut de Recherche en Cancérologie de Montpellier Institut régional de Cancérologie de Montpellier Institut Gustave Roussy Département de médecine oncologique [Gustave Roussy] Department of Mathematics [Univ California San Diego] Institut Jules Bordet [Bruxelles] Université libre de Bruxelles = Free University of Brussels Université de Bruxelles Weill Cornell Medicine [Cornell University] University of Chicago School of Electrical Engineering and Computer Science Immunologie des tumeurs et immunothérapie Université Paris-Saclay INSERM U1015, Equipe Labellisée - Ligue Nationale contre le Cancer, Villejuif, France Immunologie des tumeurs et immunothérapie Ludwig Institute for Cancer Research University of Chicago Radiothérapie Moléculaire et Innovation Thérapeutique
• Publié dans OncoImmunology le 24/10/2020

---

Résumé :

---

Fichiers liés : KONI_14_2432726.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 18/12/2024
• Auteurs : Ana Cecilia Aliaga FandinoNicolas VigneronEsteban AlfonsoJean-Philippe BurdetEric RemolifAmanda Malvessi CattaniTara Smit-SadkiStéphanie CluzetJosep Valls-FonayetPierre PétriacqMarkus Rienth
• Organismes : LRSV-Evolution des Interactions Plantes-Microorganismes Empresa Brasileira de Pesquisa Agropecuária Universidade Federal do Rio Grande do Sul [Porto Alegre – Brasil] = Federal University of Rio Grande do Sul [Porto Alegre – Brazil] Unité de Recherche Œnologie [Villenave d'Ornon] Unité de Recherche Œnologie [Villenave d'Ornon] Université de Bordeaux Plateforme Bordeaux Metabolome Haute Ecole de Viticulture et Oenologie
• Publié dans BMC Plant Biology le 22/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 18/12/2024
• Auteurs : Victor NguyenJean-Philippe MetgesMoncef MorjaniPierre-Guillaume PourreauEstelle DhamelincourtLucille QuenehervéOlivier PradierVincent Bourbonne
• Organismes : Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier Régional Universitaire de Brest Laboratoire de Traitement de l'Information Medicale Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier Régional Universitaire de Brest Laboratoire de Traitement de l'Information Medicale Laboratoire de Traitement de l'Information Medicale Centre Hospitalier Régional Universitaire de Brest
• Publié dans Radiation Oncology le 27/10/2020

---

Résumé : Introduction While there is a growing amount of data on the cardiac toxicity of radiotherapy (RT) in relation to its impact on cardiac sub-structures (CSS), there are only few studies addressing this issue in patients followed for esophageal cancer (ESOC). We aimed to evaluate the association between independent parameters of dose received by CSS and major cardiac events (MACEs) in this population. Materials and methods We retrospectively analyzed 122 patients treated with exclusive RT or chemo-RT for ESOC. Heart and CSS i.e. right atrium, left atrium (LA), right ventricle, left ventricle and myocardium, have been automatically segmented, and dose volume histogram were extracted. Cardiac events were collected focusing on the occurrence of MACEs of grade 3 or higher (G3+) and grade 4 or higher (G4+) according to the CTCAE v5.0. Results With a median follow-up of 21.9 months and in a population of high to very high cardiovascular risk (95.5%), 21 (17.2%) and 9 (7.4%) patients had G3 + and G4 + MACEs with a respective median time to event of 13.05 and 9.8 months. After multivariate analysis and among all heart and CSS-based dosimetric features, only the volume of LA receiving 15 Gy or more (V15LA) remained significantly associated with the G3 + and G4 + MACEs. The use of volumetric modulated arctherapy significantly reduced V15LA compared with 3D conformal RT. Conclusion In a cohort of ESOC patients treated with exclusive RT, incidence of MACEs was associated with V15LA, underlining the importance of CSS. These high cardiovascular (CV) risk patients should benefit from standard CV assessment and strict control of their risk factors.

---

Fichiers liés : s13014-024-02560-0.pdf

---

Source

---

• Type de publi. : Pré-publication, Document de travail
• Date de publi. : 18/12/2024
• Auteurs : Nathalie JustPierre Marie ChevillardMartine BataillerJean-Philippe DuboisPascal VaudinDelphine PillonMartine Migaud
• Organismes : Physiologie de la reproduction et des comportements [Nouzilly] Danish Research Centre for Magnetic Resonance Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly] Physiologie de la reproduction et des comportements [Nouzilly]

---

Résumé : The hypothalamus is a central structure of the mammalian brain, which controls physiological, endocrine and metabolic brain homeostasis. Despite this essential role, little is known about the normal and altered neurochemical changes occurring within the hypothalamic structures. Here, the metabolism of the hypothalamus of ewes was investigated at 3T using proton magnetic resonance spectroscopy ( 1 H-MRS). We used the sensitivity of these animals to photoperiod i.e. the ratio of day to night length, to investigate the hypothalamic metabolic changes and their relationship to hypothalamic adult neurogenesis. A longitudinal study involving 4 ewes per timepoint was conducted at 4 time points (P01, P02, P03 and P04) during long days (LD) and 4 time points during short days (SD). Significant metabolic changes were found between LD and SD at all time points in particular for glutamate (Glu), glutamine, myo-inositol and total N-acetyl-Aspartate (NAA). During SD, glutamate and glutamine concentrations were significantly smaller at P01 compared to all other time points while significant neurochemical changes occurred during the entire LD period. Neurochemical changes relative to P01 remained stable during LD and SD except for Glu and Gln which increased between P01 and P02 during SD. Relative metabolic changes were significantly higher on average for NAA and Glu and significantly smaller on average for total choline during SD compared to LD, respectively, paralleling the average changes in the numbers of neural stem cells and glial and oligodendrocyte progenitors found by immunohistochemistry. Despite important differences between MRS and immunohistochemistry in terms of spatial resolution, both techniques suggest complementary findings that should contribute to a better characterization of the hypothalamus during photoperiodism and adult neurogenesis. We conclude that 1 H-MRS could be a promising non-invasive translational technique to investigate the existence of adult neurogenesis in-vivo in gyrencephalic brains.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 13/12/2024
• Auteurs : Sélim Ben ChéhidaHeemee Devi BunwareeMurielle HoareauOumaima MoubsetCharlotte JulianLaurence BlondinDenis FillouxChristophe LavergnePhilippe RoumagnacArvind VarsaniDarren MartinJean-Michel LettPierre Lefeuvre
• Organismes : Peuplements végétaux et bioagresseurs en milieu tropical Peuplements végétaux et bioagresseurs en milieu tropical Peuplements végétaux et bioagresseurs en milieu tropical Département Systèmes Biologiques Plant Health Institute of Montpellier Plant Health Institute of Montpellier Plant Health Institute of Montpellier Plant Health Institute of Montpellier Conservatoire Botanique National de Mascarin Plant Health Institute of Montpellier Arizona State University [Tempe] University of Cape Town Peuplements végétaux et bioagresseurs en milieu tropical Peuplements végétaux et bioagresseurs en milieu tropical
• Publié dans Virus Evolution le 25/01/2017

---

Résumé :

---

Fichiers liés : Chehida-VE-2024-CC-BY.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 12/12/2024
• Auteurs : Marie RobertAlexis MathianValentin LacombeHervé LobbesLéopold AdélaïdeMaelle Le BesneraisJean-Nicolas DacherBenjamin TerrierArsène MékinianRim BourguibaSophie Georgin-LavialleJérome HadjadjYann NguyenDalila MouloudjMaël HeibligHassina AlouiChloé Mc AvoySamuel ArdoisCorrado CampochiaroAlexandre MariaCyrille CoustalThibault ComontEstibaliz LazaroFrançois LifermannGuillaume Le GuennoVincent GrobostRoderau OuthJulien CampagneAnais Dor-EtienneAlice GarnierYvan JamillouxAntoine DossierMaxime SamsonSylvain AudiaBarbara NicolasBaptiste de MalepradeBenjamin de Sainte MarieBenoit FaucherJean-David BouazizJonathan BronerCyril DumainCarole AntoineBenjamin CarpentierBrice CastelCéline Lartigau-RoussinÉtienne CrickxGeoffroy VolleDamien FayardPaul DeckerThomas MoulinetAnael DumontAlexandre NguyenAchille AoubaJean-Philippe MartellosioMatthieu LevavasseurSébastien PuigrenierPascale AntoineJean-Thomas GiraudOlivier HermineCarole LacoutNihal MartisJean-Denis KaramFrançois ChassetLaurent ArnaudPaola Marianetti GuingelChristophe DelignyThibaud ChazalPascal Woaye-HuneMarielle Roux-SauvatAurore MeyerPierre HirschNoémie AbisrorPierre FenauxOlivier KosmiderVincent JachierOlivier Fain
• Organismes : AP-HP - Hôpital Bichat - Claude Bernard [Paris] CHU Pitié-Salpêtrière [AP-HP] Centre d'Immunologie et des Maladies Infectieuses Centre Hospitalier Universitaire d'Angers CHU Estaing [Clermont-Ferrand] Institut Pascal Centre Hospitalier de Vienne Lucien Hussel Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices Hôpital Charles Nicolle [Rouen] Endothélium, valvulopathies et insuffisance cardiaque CHU Rouen Hôpital Cochin [AP-HP] Université Paris Cité CHU Saint-Antoine [AP-HP] Tunis El Manar University [University of Tunis El Manar] [Tunisia] = Université de Tunis El Manar [Tunisie] = جامعة تونس المنار (ar) CHU Tenon [AP-HP] Sorbonne Université Assistance publique - Hôpitaux de Paris (AP-HP) Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] CHU Saint-Antoine [AP-HP] Centre de recherche en Immunologie des Infections virales et des maladies auto-immunes Université Claude Bernard Lyon 1 Hospices Civils de Lyon Centre de Recherche en Cancérologie de Lyon CHU Saint-Antoine [AP-HP] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] IRCCS San Raffaele Scientific Institute [Milan, Italie] CHU Montpellier = Montpellier University Hospital Hôpital Saint Eloi [CHU Montpellier] Service Médecine interne [CHU Toulouse] Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle Centre Hospitalier Dax - Côte d'Argent CHU Estaing [Clermont-Ferrand] CHU Clermont-Ferrand Centre Hospitalier Saint Jean de Perpignan Université de Lorraine Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers Hôpital de la Croix-Rousse [CHU - HCL] Université Claude Bernard Lyon 1 AP-HP - Hôpital Bichat - Claude Bernard [Paris] Service de médecine interne et immunologie clinique (SOC 1) [CHU de Dijon] Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Imagerie Ultrasonore CHU Rouen Hôpital de la Timone [CHU - APHM] Aix Marseille Université Service des Maladies Infectieuses et Tropicales [CHU Hôpital Nord - Marseille] Immunologie humaine, physiopathologie & immunothérapie Hopital Saint-Louis [AP-HP] Centre Hospitalier Universitaire de Nîmes Centre Hospitalier Universitaire de Nîmes Université de Montpellier Aix-Marseille Université - École de médecine Hôpital Cochin [AP-HP] Centre Hospitalier de Bigorre [Tarbes] Institut Necker Enfants-Malades Institut Mondor de Recherche Biomédicale Biologie Intégrée du Globule Rouge Institut National de la Transfusion Sanguine [Paris] Laboratoire d'Excellence : Biogenèse et pathologies du globule rouge Service Médecine Interne - site Gabriel-Montpied [CHU Clermont-Ferrand] Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Ingénierie Moléculaire, Cellulaire et Physiopathologie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie UNIROUEN - UFR Santé Université de Caen Normandie - UFR Santé Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Université de Poitiers = University of Poitiers Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 Centre Hospitalier Régional Universitaire [CHU Lille]
• Publié dans JAMA Network Open le 29/10/2020

---

Résumé : This case series reports on the clinical presentation, laboratory findings, imaging characteristics, treatments, and outcomes of nonischemic cardiac manifestations in patients with VEXAS syndrome with confirmed pathogenic UBA1 alterations.

---

Fichiers liés : Vexas_cardiac_JamaNetwork2024.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 12/12/2024
• Auteurs : Sophie HennionValentyn FournierPhilippe DerambureGérald DelelisLoris Schiaratura
• Organismes : Lille Neurosciences & Cognition - U 1172 Service de neurophysiologie clinique Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 Psychologie : Interactions, Temps, Emotions, Cognition (PSITEC) - ULR 4072 Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 Service de neurophysiologie clinique Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 Psychologie : Interactions, Temps, Emotions, Cognition (PSITEC) - ULR 4072
• Publié dans Epilepsy & Behavior le 22/10/2020

---

Résumé : People with epilepsy face stigma that impacts numerous aspects of their daily lives. Although the stigma surrounding people with epilepsy has been extensively documented, the mechanisms underlying it—such as cultural stereotypes—remain to be explored. Cultural stereotypes are widely shared beliefs within a cultural context about attributes typically associated with members of a particular group. This study, conducted within French society, has two primary objectives: 1) to define the content of cultural stereotypes associated with people suffering from epilepsy and 2) to examine how familiarity and knowledge about epilepsy influence these stereotypes. To explore these stereotypes, a free association task was conducted across three cultural groups (n = 96): (1) the general population, with low familiarity and knowledge about epilepsy (n = 39); (2) healthcare professionals without epilepsy specialization, who have more familiarity and knowledge than the general population (n = 38); and (3) healthcare professionals specialized in epilepsy, who have the highest familiarity and knowledge of the three groups (n = 29). All participants held higher education qualifications to ensure a more homogeneous socio-cultural background across groups. Using the software program “IraMuTeQ”, we analyzed the diversity of terms each group associated with “people with epilepsy.” Additionally, we examined the valence and typicality of cultural stereotypes in each group. The results reveal that, regardless of familiarity and knowledge levels, cultural stereotypes linked to epilepsy are generally negative. Across the entire sample, the most prototypical associations with people with epilepsy included “madness,” “possession,” “tongue,” and “intellectual deficiency.” The general population shares some cultural stereotypes with non-specialized healthcare professionals (e.g., “photosensitivity”), while non-specialized professionals share other associations with specialized healthcare professionals (e.g., “intellectual deficiency” and “mental illness”). However, no overlap was found between the cultural stereotypes of the general population and those of healthcare professionals specialized in epilepsy. Stereotypes related to epilepsy appear to be less typical among healthcare professionals compared to the general population. This distinction between cultural stereotypes and personal beliefs is further discussed below. Considering cultural stereotypes may allow for more tailored and effective interventions to reduce epilepsy-related stigma by addressing specific socio-cultural groups. Further research within a cross-cultural approach is recommended to deepen these findings.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 12/12/2024
• Auteurs : Dominique PloinMathilde AlexandreBruno VentelouDidier CheBruno CoignardNathalie BoulangerChristophe BurucoaFrançois CaronPierre GallianYves HansmannChristian LienhardtPhilippe MinodierHenri PartoucheMathieu RevestNadia SaidaniGilles SalvatNicolas VignierSylvie FloreaniSabine HenryBruno PozzettoBruno HoenEmmanuelle GodeauJean-Marie JanuelMarion PorcherieFlorence Bodeau-Livinec
• Organismes : Hôpital Femme Mère Enfant [CHU - HCL] Center for Interdisciplinary Research and Innovation Commission Spécialisée Maladies infectieuses et maladies émergentes Commission Spécialisée Maladies infectieuses et maladies émergentes Centre National de la Recherche Scientifique Aix Marseille Université Aix-Marseille Sciences Economiques Santé publique France - French National Public Health Agency [Saint-Maurice, France] Santé Publique France, Occitanie [Toulouse, France] Centre National de référence des Borrelia Commission Spécialisée Maladies infectieuses et maladies émergentes Pathogens Host Arthropod Vectors Interfaces Pharmacologie des anti-infectieux et antibiorésistance [U 1070] Université de Poitiers – UFR Santé [Faculté de Médecine et de Pharmacie] Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Commission Spécialisée Maladies infectieuses et maladies émergentes Service des maladies infectieuses et tropicales [Rouen] Dynamique Microbienne associée aux Infections Urinaires et Respiratoires Unité des Virus Emergents Établissement Français du Sang [La Plaine Saint-Denis] Commission Spécialisée Maladies infectieuses et maladies émergentes Commission Spécialisée Maladies infectieuses et maladies émergentes Centre Hospitalier Universitaire [Strasbourg] Commission Spécialisée Maladies infectieuses et maladies émergentes Assistance Publique - Hôpitaux de Marseille Commission Spécialisée Maladies infectieuses et maladies émergentes Commission Spécialisée Maladies infectieuses et maladies émergentes Département de Médecine Générale ARN bactériens et médecine Commission Spécialisée Maladies infectieuses et maladies émergentes Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes] Centre Hospitalier Intercommunal de Cornouaille Commission Spécialisée Maladies infectieuses et maladies émergentes Direction de la Stratégie et des Programmes Commission Spécialisée Maladies infectieuses et maladies émergentes Hôpital Avicenne [AP-HP] Commission Spécialisée Maladies infectieuses et maladies émergentes Infection, Anti-microbiens, Modélisation, Evolution Haut Conseil de la Santé Publique Commission Spécialisée Maladies infectieuses et maladies émergentes Commission Spécialisée Maladies infectieuses et maladies émergentes Centre International de Recherche en Infectiologie Service des Agents Infectieux et Hygiène [CHU Saint-Etienne] INterdisciplinarité en Santé Publique Interventions et Instruments de mesure complexes Commission Spécialisée Maladies infectieuses et maladies émergentes École des Hautes Études en Santé Publique Arènes: politique, santé publique, environnement, médias Département des sciences humaines et sociales Centre d'Epidémiologie et de Recherche en santé des POPulations Université de Rennes École des Hautes Études en Santé Publique Institut du Management Université de Rennes École des Hautes Études en Santé Publique Département des sciences humaines et sociales Arènes: politique, santé publique, environnement, médias Université de Rennes École des Hautes Études en Santé Publique Institut de recherche en santé, environnement et travail Université de Rennes Département Méthodes quantitatives en santé publique
• Publié dans Eurosurveillance le 28/10/2020

---

Résumé : Within the International Health Regulations framework, the French High Council for Public Health was mandated in 2022 by health authorities to establish a list of priority infectious diseases for public health, surveillance and research in mainland and overseas France. Aim Our objective was to establish this list. Methods A multi-criteria decision analysis was used, as recommended by the European Centre for Disease Prevention and Control. A list of 95 entities (infectious diseases or groups of these, including the World Health Organization (WHO)-labelled ‘Disease X’) was established by 17 infectious disease experts. Ten criteria were defined to score entities: incidence rate, case fatality rate, potential for emergence and spread, impact on the individual, on society, on socially vulnerable groups, on the healthcare system, and need for new preventive tools, new curative therapies, and surveillance. Each criterion was assigned a relative weight by 77 multidisciplinary experts. For each entity, 98 physicians from various specialties rated each criterion against the entity, using a four-class Likert-type scale; the ratings were converted into numeric values with a nonlinear scale and respectively weighted to calculate the entity score. Results Fifteen entities were ranked as high-priorities, including Disease X and 14 known pathologies (e.g. haemorrhagic fevers, various respiratory viral infections, arboviral infections, multidrug-resistant bacterial infections, invasive meningococcal and pneumococcal diseases, prion diseases, rabies, and tuberculosis). Conclusion The priority entities agreed with those of the WHO in 2023; almost all were currently covered by the French surveillance and alert system. Repeating this analysis periodically would keep the list updated.

---

Fichiers liés : eurosurv-29-50-4.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 12/12/2024
• Auteurs : Habeeb YusuffPierre-Emmanuel ZornCéline GiraudeauBenoit WachPhilippe ChoquetS ChatelinJean-Philippe Dillenseger
• Organismes : Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Hôpitaux Universitaires de Strasbourg Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Hôpitaux Universitaires de Strasbourg Faculté de médecine, maïeutique et sciences de la santé [Strasbourg] Fédération de Médecine Translationnelle de Strasbourg Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie Hôpitaux Universitaires de Strasbourg Faculté de médecine, maïeutique et sciences de la santé [Strasbourg] Fédération de Médecine Translationnelle de Strasbourg
• Publié dans Magnetic Resonance Materials in Physics, Biology and Medicine le 27/10/2020

---

Résumé : Purposes: This research highlights the need for affordable phantoms for MRI education. Current options are either expensive or limited. A phantom, easy to manufacture and distribute, is proposed to demonstrate various pedagogical concepts, aiding students in understanding MRI image quality concepts. Methods: We designed a cylindrical MRI phantom that comprises sections that can be filled with chosen liquids and gels. The dimensions were chosen to fit most consumer-grade 3D printers, facilitating widespread dissemination. It includes five modular sections for evaluating spatial resolution, geometrical accuracy, slice thickness accuracy, homogeneity, and contrast. Results: The modular cylindrical MRI phantom was successfully fabricated. Each section of the phantom was tested to ensure it met the specified pedagogical needs. The spatial resolution section provided clear images for evaluating fine details. The geometrical accuracy section allowed for precise measurement of distortions. The slice thickness accuracy section confirmed the consistency of slice thickness across different MRI sequences. The homogeneity section demonstrated uniform signal distribution, and the contrast section effectively displayed varying contrast levels. Conclusions: This modular MRI phantom offers a cost-effective tool for educational purposes in MRI. Its design enables educators to demonstrate multiple pedagogical scenarios with a single object. The phantom’s compatibility with consumer-grade 3D printers and its modularity makes it accessible and adaptable to various educational settings. Future work could explore further customization and enhancement of the phantom to cover additional educational needs. This tool represents a significant step toward improving MRI education and training by providing a practical, hands-on learning experience.

---

Fichiers liés : 2024 Yusuff MRM.pdf

---

Source

---

• Type de publi. :
• Date de publi. : 06/12/2024
• Auteurs : Jose Villasboas BisnetoDanielle WallaceFrancesc BoschCarlos Grande GarciaStephen SmithAntonio PintoReid MerrymanNorma GutierrezJean-Pierre MarolleauLuca ArcainiCristina GarcíaRocío Figueroa MoraBrian TillRosaria de FilippiSara RattottiLucie AubergeonLaurent ChêneJan FagerbergPier Luigi ZinzaniPhilippe ArmandJonathan FriedbergStephen Ansell
• Organismes : Mayo Clinic [Rochester] Wilmot Cancer Institute [Rochester] Vall d'Hebron University Hospital [Barcelona] Universidad de Navarra [Pamplona] Fred Hutchinson Cancer Research Center [Seattle] Istituto Nazionale Tumori IRCCS Fondazione G. Pascale [Naples, Italy] Dana-Farber Cancer Institute [Boston] Instituto de Investigación Biomédica de Salamanca CHU Amiens-Picardie HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 Fondazione IRCCS Policlinico San Matteo [Pavia] Vall d'Hebron University Hospital [Barcelona] Universidad de Navarra [Pamplona] Fred Hutchinson Cancer Research Center [Seattle] Istituto Nazionale Tumori IRCCS Fondazione G. Pascale [Naples, Italy] Fondazione IRCCS Policlinico San Matteo [Pavia] Università degli Studi di Pavia [Italia] = University of Pavia [Italy] = Université de Pavie [Italie] Enterome Enterome Enterome Alma Mater Studiorum Università di Bologna = University of Bologna [Bologne] Dana-Farber Cancer Institute [Boston] University of Rochester Medical Center Mayo Clinic [Rochester]

---

Résumé : Background Follicular and marginal zone B cell lymphoma (FL; MZL) demonstrate an indolent course with heterogeneous outcomes and a potential for spontaneous remissions indicating immune system intervention. T cell-based therapeutic approaches are therefore an attractive proposition in FL and MZL. EO2463 peptide immunotherapy expands pre-existing memory CD8 T cells recognizing non-self-protein sequences from gut bacteria which cross-react with B cell antigens. The compound includes 4 HLA-A2 synthetically produced epitopes which exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), as well as a the CD4 helper-epitope UCP2 derived from hTERT. EO2463 is being used to drive anti-tumor immunity against B cell malignancies, and has demonstrated long-lasting, specific CD8-memory T cell responses and clinical activity in relapsed/refractory FL and MZL [J Clinical Oncol 2024, 42 (S16), 7058]. Furthermore, CD8 T cells expanded from samples of patients (pts) treated with EO2463 can kill HLA-A2 expressing lymphoblastoid cell lines presenting the B cell targets [Hematological Oncol 2023, 41 (S2), 581-582]. Methods The current report describes testing of a possible biomarker in the phase 1 portion of the ongoing EONHL1-20/SIDNEY trial (NCT04669171).This part of the trial (“Cohort 1”) included pts (n=9) with relapsed (at least 1, no limit, prior treatments) FL and MZL, stage 1-3A, confirmed to be positive for HLA-A2. Pts received EO2463 (150 [n=3] or 300μg/peptide [n=6]) SC with adjuvant Montanide ISA 51 VG q2 weeks (w) x 4, then q4w, for a max of 12 months; at w7 lenalidomide (20 mg/day for 21/28 days up to 12 cycles) was added (EL), and if no complete remission (CR) at w19, rituximab (375 mg/m IV, q1w x 4, then q4w x 4) was also added (ER2). Immune responses and clinical outcomes of Cohort 1 were previously reported [J Clinical Oncol 2024, 42 (S16), 7058]. To assess a possible biomarker, tetramers were used to specifically detect CD8 T cells recognizing the 4 epitopes in the EO2463 compound (derived from gut bacterial proteins exhibiting molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268). The tetramers were all marked with phycoerythrin. Thawed samples of peripheral blood mononuclear cells taken at start of w5 (after 2 administrations of EO2463 monotherapy, each followed by 2w observation) were stained ex vivo (without any in vitro stimulation) with the tetramers and assayed by flow cytometry. Results are presented as percentage of EO2463 specific CD8 T cells among all CD8 T cells in the peripheral blood of the pt. Results Among the 9 treated pts, PET-CT at w6 (after 3 administrations of EO2463 monotherapy) suggested possible clinical activity in 4/9 pts (1 PR, 1 pt size reduction 15%, 1 pt 20% reduced tracer uptake, 1 pt 5/6 target lesions reduced metabolic activity). By PET-CT at w42 (after 12 administrations of EO2463 monotherapy, 11 cycles of lenalidomide, and rituximab treatment) the Lugano response assessment was complete response in 6/9 pts. A positive biomarker response was assessed in 5/9 pts (percentage of specific CD8 T cells ranged from 0.2-2.1%). EO2463 monotherapy PET-CT activity at w6 (n=4/9 pts): 4 of 4 pts with clinical activity were biomarker positive and 1/5 of the other pts was also positive; this pt had an isolated increase in FDG-uptake at w6, followed by a CR at w19. Four further other pts were biomarker negative. In this limited sample, the biomarker had sensitivity 100% and specificity 80%. EO2463 in combination with lenalidomide/rituximab PET-CT CR at w42 (n=6/9): 5 of 6 pts with CR were biomarker positive and 1 pt with CR was negative; the pt with a negative test had no objective tumor response until after rituximab. In this limited sample, the biomarker showed sensitivity 83% and specificity 100%. Conclusions The current preliminary assessment indicates that direct ex vivo tetramer staining for specific CD8 T cells after short term (5 w) treatment with EO2463 monotherapy could be a possible biomarker for clinical response, both for EO2463 monotherapy response, and for response to EO2463 in combination with lenalidomide/rituximab. We plan to validate these findings in the ongoing study cohorts of the trial; expansion phase 2 cohorts, exploring EO2463 monotherapy in the “watch & wait” setting, EO2463 plus rituximab for 1st line FL/MZL, and EO2463/lenalidomide +/- rituximab in relapsed FL/MZL.

---

Source